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Beta-Adrenergic Blocking Agents in the Treatment of Patients After
a Myocardial Infarction

Sidney Goldstein, MD'

Beta-adrenergic blocking agents have been widely used in ischemic heart disease. They have
achieved their greatest benefit in the secondary prevention of recurrent events in patients foltowing
acute myocardial infarction (Ml). This is a review ofthe major clinical investigations exploring the
effects of beta-adrenergic blocking agents in patients following acute Ml and in a variety of patient
subsets. These data indicate that the routine use of beta-adrenergic blocking agenls in postinfarction
patients resutts in a 25% to 35% decrease in mortality and has increased relative and absolute benefit
in patients with ventricular ectopy and left ventricular dysfunction. The adverse effects trf betaadrenergic blocking agents are discussed which indicate that these drugs are welt tolerated wdh litde
or no side effects. This review supports the obsen/ation that beta-adrenergic blocking agents have an
important role in the treatment of patients following an acute Ml, with the exclusion of those with
chronic lung disease and severe left ventricular dysfunction. (Henry Ford Hosp Med J 1991:39:
200-5)

B

eta-adrenergic blocking agents represent the current therapeutic foundation for the treatment of patients with acute
and chronic coronary heart disease. Although this review deals
with the use of these agents in the secondary prevention of
postinfarction morbidity and mortality, their use in the treatment of hypertension and chronic angina pectoris should also be
emphasized.
Clinical investigation of beta-blockers in ischemic heart disease began almost three decades ago with the initial observations by Ahlquist (1) who demonstrated the presence of (3adrenergic receptors in the cardiovascular system. The presence
of p-adrenergic receptors led Black et al (2) to develop drugs
that could block these receptors, thereby decreasing blood pressure, pulse rate, and the metabolic requirements of the heart. A
series of preliminary clinical studies almost two decades ago described the benefit of p-adrenergic blocking agents in the treatment of patients who have sustained acute myocardial infarction
(Ml) (3-6). The results of these studies were confirmed by two
m.ajor clinical trials of almost 7,000 patients, the Norwegian
Multicenter Study (7) and the Beta-Blocker Heart Attack Trial
(8) which examined the beta-blockers timolol and propranolol,
respectively. Since these initial studies, reexamination of the
original beta-blocker studies confirmed the inifial observafions
of their benefit when administered to patients after an acute M I .

sure of its effect on improving survival (9) (Fig I ) . In addition to
limiting infarct size, they modify the expression of ventricular
ectopy both in the acute and chronic phases of M l . Whether this
is a result of modifying myocardial ischemia or due to an independent antiarrhythmic effect is not entirely clear. Animal studies demonstrate that beta-blockers exhibit a dose response effect
on ventricular fibrillafion threshold when studied in both ischemic and nonischemic states (10). It is therefore clear that padrenergic blocking agents have the potential of modifying two
of the major risks facing patients with ischemic heart disease;
the progression of myocardial ischemia and the development of
life-threatening arrhythmias. In addition, Kaplan et al (11) demonstrated that propranolol therapy was able to modulate diet-induced coronary atherosclerosis in male cynomolgus monkeys
by altering their behavioral response to stress. Cruickshank (12)
reviewed the multiplicity of potential effects that these agents
have on altering the progression of coronary artery disease.

Mechanism of Action of Beta-Blockers

Beta-adrenergic blocking agents differ in their physiologic
and pharmacologic effects. The major difference relates to the
presence of P, selectivity. Metropolol, atenolol, and betaxalol,
for instance, are considered drugs which have p, receptor blocking ability. These drugs tend to have a predominant, but not exclusive, effect on chronotropic and inotropic blockade without
affecting Pj receptors which cause peripheral vasoconstriction
and bronchial constriction. The nonselective drugs such as propranolol, timolol, and nadolol do not have this selectivity and
block both P, and P, receptors. It should be emphasized, how-

The initial studies by Black et al (2) demonstrated that betablockers lower heart rate and blood pressure. These two physiologic effects result in the modification of myocardial oxygen demands resulting in a salutary effect on the jeopardized ischemic
myocardial tissue. It has been proposed that the degree to which
pulse rate decreases as a result of beta-blocker therapy is a mea-
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ever, that this P, selecfivity is expressed at relatively low doses
and is usually lost in the higher dose range. An additional unique
characteristic of these agents is the intrinsic sympathomimetic
or p-agonist effect. This can be expressed to a varying degree by
a positive inotropic or chronotropic effect as seen with oxprenolol, pindolol, or acebutolol. All of these characteristics provide
a spectrum of drugs available to the physician in the treatment of
many forms of cardiovascular disease including hypertension,
angina, and arrhythmias. The only drugs which have been tested
on mortality in the chronic phase of acute Ml are propranolol
(8), timolol (7), metoprolol (13), atenolol (14), sotalol (15),
acebutolol (16), pindolol (17), and oxprenolol (18). All but pindolol and oxprenolol have demonstrated a salutary effect on
mortality.

50p

40 03

tr
o

A series of clinical trials examined the effect of different betablockers on mortality (Table 1). The largest body of information
has been reported by the Norwegian Multicenter Study Group
(7) and the Beta-Blocker Heart Attack Trial (8). Timolol was administered in doses of 10 mg twice daily and propranolol in
doses of 60 to 80 mg three times a day. These two studies indicate that when either timolol or propranolol was administered
within two to three weeks postinfarction, a decrease in mortality
between 25% and 36% in the first two years could be achieved,
when compared to control patients receiving placebo (Figs 2
and 3). In addition, in the timolol study a significant reduction in
reinfarction and sudden death was observed in the active treatment group.
The relafive benefit of these drugs has been examined prospectively and retrospectively in a number of different patient
subsets and found to be consistentiy similar in almost all subgroups studied. The use of beta-blockers relative to infarct location supports their efficacy, regardless of anterior or inferior infarction. Anterior infarcts, in general, have a placebo mortality
rate twice that of inferior infarctions. The absolute benefit of
these drugs relates to the inherent mortality risk of the particular
subgroups. For example, patients who have experienced an anterior MI or who are older have a higher placebo mortality rate
and therefore will achieve a greater total decrease in mortality as
a result of beta-blocker therapy. The one exception are patients
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Fig 1—Relationship between heart rate and reduction in mortality induced by beta-blockers in survivors of acute MI. Note
that beta-blockers with signiflcant intrinsic sympathomimetic
activity (open circles) with little or no hradycardlc effect exert
little effect on mortality. Beta-blockers without intrinsic sympathomimetic activity (closed circles) with hradycardlc effect have
the most significant effect on mortality. (From Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in
acute and long-term myocardial infarction intervention trials.
Am J Cardiol I986;57;43F-49F. Reprinted with permission.)

who experienced a non-Q wave MI who achieve a less apparent
benefit. Subgroup analyses demonstrate no significant effect of
propranolol or metoprolol in patients with a non-Q wave acute
MI (19,20). In contrast, the timolol-treated patients with a nonQ wave acute MI experienced a significant reduction in mortality (21).
A number of different subgroups have been analyzed in order
to ideniify those patients who can achieve the greatest benefit
from beta-blocker therapy. In postinfarction pafients between
65 to 75 years of age, fimolol exerted a similar decrease in reinfarction and death (22), indicating its efficacy regardless of age.
Jafri et al (23) examined the effect of propranolol on smokers
(Fig 4) and observed that the greatest beneficial effect of pro-

Table 1
Selected Results of Long-Term Beta-Blocker Trials for Secondary Prevention After Acute Myocardial Infarction

Trial
Multicentre Intemational Study (1975) (6)
Norwegian Multicenter Study (1981) (7)
Julian et al (1982) (15)
Beta-Blocker Hean Attack Trial (1982) (8)
Taylor et al (1982) (18)
Boissel et al(1990)(16)

Numt)er of
Patients

Beta-Blocker

Entry From
M I (Days)

3,053
1.884
1,456
3,738
1,103
607

Practolol
Timolol
Sotalol
Propranolol
Oxprenolol
Acebutolol

1.0
11.5
8.3
13,8
14 months
2-22

Mean
Follow-up
(Months)
24
17
12
25
48
10

Mortality
Drug
Placebo

Reinfarction
Drug
Placebo

(%)

(%)

(%)

(%)

6,3
10,4
7,3
7.2
9,5
5,7

8,2*
16.2*
8.9
9.8*
10,2
11,0*

4
10
3
4
1 1
2

4
14*
4
5*
12
1,3

•Statistically significanl difference.
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Fig 2—Life-table cumulative mortality curves for groups receiving piopranolol hydrochloride or placebo. N indicates total
number of patients followed-up through each time point. (From
the Beta-Blocker Heai-t Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial
infarction. I. Mortality results. JAMA 1982;247:1707-14. Reprinted with permission.)
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pranolol on mortality was achieved in patients who smoked before their MI and those who continued to smoke after the event.
Similar observations with timolol treatment were made by Ronnevik et al (24).
The duration of therapy in these trials was limited to two to
three years. The beneficial effects of therapy persisted throughout that time. The Norwegian Multicenter Study on timolol was
later extended to seven years, during which a continued beneficial effect was observed (25). The effect of withdrawal of metoprolol in postinfarction patients was investigated after five
to six years of therapy (26). Associated with metoprolol withdrawal was an observed increase in symptoms and mortality in
patients, when compared to patients who continued therapy. A
recent study examined the risk of hospital death in patients taking a beta-blocker before a MI (27). That study indicated that
prior beta-blocker therapy reduced the risk and severity of the
subsequent acute infarction. Although ventricular fibrillafion
was similar in patients regardless of prior beta-blocker therapy,
patients taking a beta-blocker at the time of admission had a reduced extent of infarcfion and risk of death during the 28-day
period after an acute MI.

Effect of Beta-Blockers on
Ventricular Arrhythmias
Ventricular ectopy, of course, has been a major predictor of
both sudden death and long-term mortality in patients following
MI. Observations in the Beta-Blocker Heart Attack Trial (28)
demonstrated that the use of propranolol decreased the frequency of ventricular ectopy in the first six weeks after the
event. In patients with complex ventricular ectopy, propranolol
therapy resulted in a greater decrease in mortality rate when
compared to those patients without complex ventricular premature beats (29) (Fig 5). The effect of beta-blockers on mortality
in patients with high-frequency ventricular ectopy is not solely
related to ventricular ectopic beat suppression. It appears that
they may also modify the biological milieu in which ventricular
ectopy occurs, presumably rendering them less malignant.
A number of studies examined the relafionship of betablocker therapy on arrhythmias and hypokalemia and their effect on hypokalemia in patients receiving concomitant diuretic
therapy. Patients taking a beta-blocking agent prior to their MI
had higher serum potassium and less frequent ventricular ectopy
on admission (30). This is presumedly due to the interference
with NaK ATPase by Pj receptor blockade, preventing the intracellular movement of K-F which occurs in the setting of increased serum catecholamine associated with stress (31).
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Fig 3—Effect of timolol on mortality from all causes. (From the
Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute
myocardial infarction. N Engl J Med 1981 ;304:801-7. Reprinted with permission.)
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Effect of Beta-Blockers in Patients with
Decreased Left Ventricular Function
Treatment with beta-blockers in postinfarction patients with
left ventricular dysfunction has been of particular interest. Some
concem was initially raised regarding the potential dangers of
beta-blockers in patients with heart failure. Patients with severe
left ventricular dysfunction manifested by shock and overt congestive heart failure were excluded from most beta-blocker trials. In the Beta-Blocker Heart Attack Trial, patients were in-
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Fig 4—Survival in smokers following MI was better in patients receiving propranolol in comparison to
placebo. (From Jafri SM, Tilley BC, Peters R, Schultz LR, Goldstein S. Effects of cigarette smoking and
propranolol in survivors of acute myocardial Infarction. Am J Cardiol 1990:65:271-6. Reprinted with permission.)

eluded who had congestive heart failure but whose heart failure
was stabilized with digitalis and diuretic therapy. In those patients with a history of heart failure, propranolol therapy had the
most profound beneficial effect on mortality (32) (Fig 6). Although there was a slight increase in heart failure in the initial
phases of the treatment of these patients, beta-blockers were
well tolerated. In a similar study in patients with complex arrhythmias and ventricular dysfunction, propranolol was also
demonstrated to decrease sudden death significantly (33). A recent analysis of the patients who received placebo in the Multicenter Diltiazem Postinfarction Trial (34) further confirmed
these observations. Patients with evidence of heart failure and a
left ventricular ejection fraction less than 30% and who received
a beta-blocker had approximately a 50% decrease in mortality
when compared to those who were not taking beta-blockers (Fig
7). Although beta-blockers should be used cautiously in patients
with left ventricular dysfunction, these patients have the greatest
potential for benefit.

Side Effects of Beta-Blocker Therapy
Although it is suggested that beta-blockers are poorly tolerated due to a host of presumed adverse effects, blinded randomized placebo-controlled trials fail to support this presumption.
The Beta-Blocker Heart Attack Trial extensively examined the
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Fig 5—Effect of propranolol on mortality and sudden death in
relation to the presence of complex ventricular premature beats
(VPBs), > 10/hr or i-uns or multiforms on 24-hour Holler monitor at baseline. (Adaptedfrom Freidman LM, Byington RP, Capone RJ, Furherg CD, Goldstein S, Lichstein E,for the BetaBlocker Heart Attack Trial Research Group. Effect of propranolol in patients with myocardial infarction and ventricular
arrhythmia. J Am Coll Cardiol 1986;7:1-8. Reproduced wfth
permission.)
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adverse effects of propranolol (8). Although patients with obstructive pulmonary disease were excluded from the study, there
was a slight increase in bronchospasm and tiredness in patients
taking propranolol (Table 2). Neuropsychiatric symptoms such
as depression, nightmares, and insomnia did not occur any more
frequently in patients receiving propranolol than in those receiving placebo. It is therefore clear that these drugs are well tolerated. Much of the perceived psychological reactions associated
with beta-blocker therapy may in fact be related lo the increased
occurrences of these symptoms in patients who experience a MI.

I
0

CHF

No CHF
Total
Mortality

CHF

No CHF

CHF

Cardiovascular
Mortality

Propranolol
Placebo

No CHF

Sudden
Death

Fig 6—The effect of propranolol on mortality in relation to a
history of heart failure (CHF) at baseline in the Beta-Blocker
Heart Attack Trial. (Adapted from Chadda K. Goldstein S, Byington R, Curb JD. Effect ofpropranolol after acute myocardial
infarction in patients with congestive heart failure. Circulation
1986;73:503-10. Reproduced whh permission.)
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One additional concem has been the effect of these dmgs on
blood lipids. A recent analysis by Byington et al (35) of the
Beta-Blocker Heart Attack Trial indicates that although there is
a slight decrease in high-density lipoprotein cholesterol and an
increase in triglycerides, there is no change in low-density lipoprotein cholesterol. When mortality data were analyzed relative
to these changes, propranolol continued to exert a profound beneficial effect on mortality regardless of its effect on blood lipids.
It appears, therefore, that these effects on serum lipids are of no
importance either in the short- or long-term therapy of MI patients.
These studies, as well as retrospective examinations of clinical trials of beta-blockers, continue to develop data to support
the benefits of the routine use of these dmgs in postinfarction
patients. Their use appears to be indicated in all patients except
those who have contraindications to their use. Beta-blockers appear to have their most significant absolute effect on high-risk
patients including those with complex ventricular ectopy and
left ventricular dysfunction. Therapy should be continued for
the life of the patient, based on residual beneficial effects observed at seven years following the acute event.

Beta blocker
No beta blocker
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